Rubicon Research Limited

Based in Maharashtra, India, co-founded by Pratibha Pilgaonkar, Sudhir Pilgaonkar and Maharukh Rustomjee. Rubicon Research Limited, formerly known as Rubicon Research Private Limited specializes in pharmaceutical formulations, providing a range of specialty pharmaceuticals and drug-device combination products for regulated markets, particularly the United States. Founded in 1999 and headquartered in Mumbai, India, Rubicon Research Pvt. Ltd.

focuses on pharmaceutical formulations. In April 2026, Rubicon Research Pvt. Ltd. , a portfolio company of General Atlantic, agreed to acquire an 85% majority stake in Arinna Lifesciences Ltd.

for INR 1. 759 billion, or INR 158. 23 per share. The deal was completed later in April 2026, while founder of Arinna Lifesciences Vivek Seth retained a 15% stake and continued as Managing Director.

Parag Sancheti is the current CEO of the company. Rubicon Research Limited develops and manufactures generic and specialty pharmaceutical products across multiple dosage forms, including oral solids, liquids, ophthalmic, nasal, injectable, topical, and drug‑device combinations. The company also offers formulation development, contract development and manufacturing (CDMO), regulatory support, and life‑cycle management services to global pharmaceutical partners. Rubicon Research’s revenue streams expanded to include domestic sales of CNS‑focused branded formulations across India, supported by Arinna’s portfolio of 60+ chronic therapy brands and a network of over 4,000 prescribers.

The recent investment of INR 10 billion from General Atlantic will be utilized to support these initiatives, enhancing their research capabilities and accelerating the development of innovative pharmaceutical solutions. This strategic funding is expected to bolster their efforts in expanding into targeted regions and launching new products, thereby driving future growth.